common.study.topics.clinical

Testing Experimental Medication in Healthy Subjects

common.study.values.description

“FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects”

The study will comprise primarily a single-ascending dose (SAD) escalation component.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - GFB-887

IMP

Drug - Placebo

Matching

participant.views.study.view.additional

participant.views.study.view.scientific-title

A First-In-Human, Phase 1, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GFB-887, a TRPC5 Channel Inhibitor, in Healthy Subjects

common.study.values.clinical-trial-id

NCT03970122

participant.views.study.view.id

bW60Ea